Home
IBRX
IBRX News

Latest ImmunityBio Inc. (IBRX) News on February 22, 2025

Apple unveils iPhone 16e, Arista reports Q4 beat: Morning Buzz

TipRanks

2 days ago

Apple unveils iPhone 16e, Arista reports Q4 beat: Morning Buzz

FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage

Business Wire

3 days ago

FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage

ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

Business Wire

9 days ago

ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer

Business Wire

24 days ago

ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer

Exploring High Growth Tech Stocks in the United States

Simply Wall St.

25 days ago

Exploring High Growth Tech Stocks in the United States

ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

Business Wire

a month ago

ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ

ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom

Business Wire

a month ago

ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom

ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency

Business Wire

a month ago

ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency

ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective

Business Wire

2 months ago

ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective

High Growth Tech Stocks to Watch in December 2024

Simply Wall St.

2 months ago

High Growth Tech Stocks to Watch in December 2024

D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering

GlobeNewswire

2 months ago

D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering

ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock

Business Wire

2 months ago

ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock

ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock

Business Wire

2 months ago

ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock

Immunitybio Inc. (IBRX): Among the Most Promising Cancer Stocks According to Hedge Funds

Insider Monkey

3 months ago

Immunitybio Inc. (IBRX): Among the Most Promising Cancer Stocks According to Hedge Funds

ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment

PR Newswire

3 months ago

ImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data Fulfillment

High Growth Tech Stocks To Watch In November 2024

Simply Wall St.

3 months ago

High Growth Tech Stocks To Watch In November 2024

ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months

Business Wire

3 months ago

ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months

ImmunityBio Reports Third-Quarter 2024 Financial Results

Business Wire

3 months ago

ImmunityBio Reports Third-Quarter 2024 Financial Results

GuruFocus.com

4 months ago

ImmunityBio Soars 56% in a Day: Is This Cancer Breakthrough the Next $30 Stock?

First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma

Business Wire

4 months ago

First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma

ImmunityBio to Participate in the Jefferies London Healthcare Conference

Business Wire

4 months ago

ImmunityBio to Participate in the Jefferies London Healthcare Conference

ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer

Business Wire

5 months ago

ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer

ImmunityBio’s ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval

Business Wire

6 months ago

ImmunityBio’s ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval

ImmunityBio Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial Cancer

Business Wire

7 months ago

ImmunityBio Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial Cancer

Chief Scientific Officer Patrick Soon-Shiong, ImmunityBio, Inc.'s (NASDAQ:IBRX) largest shareholder sees value of holdings go down 6.5% after recent drop

Simply Wall St.

7 months ago

Chief Scientific Officer Patrick Soon-Shiong, ImmunityBio, Inc.'s (NASDAQ:IBRX) largest shareholder sees value of holdings go down 6.5% after recent drop

ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors

Business Wire

8 months ago

ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors

ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update

Business Wire

8 months ago

ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update

Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast

Business Wire

9 months ago

Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast

ImmunityBio First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

9 months ago

ImmunityBio First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®

Business Wire

10 months ago

ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®

ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types

Business Wire

10 months ago

ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types

ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association

Business Wire

10 months ago

ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association

ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer

Business Wire

10 months ago

ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer

ImmunityBio's bladder cancer therapy wins FDA approval

Yahoo Finance Video

10 months ago

ImmunityBio's bladder cancer therapy wins FDA approval

ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Business Wire

10 months ago

ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy

Business Wire

a year ago

NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy

N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study

Business Wire

a year ago

N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study

ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial

Business Wire

a year ago

ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial

ImmunityBio, Inc. (NASDAQ:IBRX): When Will It Breakeven?

Simply Wall St.

a year ago

ImmunityBio, Inc. (NASDAQ:IBRX): When Will It Breakeven?

ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG

Business Wire

a year ago

ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG

‘Kubrick’ Review: The Perfectionist and His Craft

The Wall Street Journal

a year ago

‘Kubrick’ Review: The Perfectionist and His Craft

Trump Tower Lender Calls Fear of Bank Property Turmoil Overblown

Bloomberg

a year ago

Trump Tower Lender Calls Fear of Bank Property Turmoil Overblown

New Strong Buy Stocks for February 2nd

Zacks

a year ago

New Strong Buy Stocks for February 2nd

Associated Press Finance

a year ago

Cavco: Fiscal Q3 Earnings Snapshot

AMN Healthcare to Hold Fourth Quarter and Full Year 2023 Earnings Conference Call on Thursday, February 15, 2024

GlobeNewswire

a year ago

AMN Healthcare to Hold Fourth Quarter and Full Year 2023 Earnings Conference Call on Thursday, February 15, 2024

Cavco Industries Reports Fiscal 2024 Third Quarter Results and Announces New $100 Million Stock Repurchase Program

GlobeNewswire

a year ago

Cavco Industries Reports Fiscal 2024 Third Quarter Results and Announces New $100 Million Stock Repurchase Program

The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks

Investor's Business Daily

a year ago

The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks

Constellium to Report Fourth Quarter and Full Year 2023 Results on February 21, 2024

GlobeNewswire

a year ago

Constellium to Report Fourth Quarter and Full Year 2023 Results on February 21, 2024

A Motley Fool Co-Founder's Roller-Coaster Nvidia Story

Motley Fool

a year ago

A Motley Fool Co-Founder's Roller-Coaster Nvidia Story

GlobeNewswire

a year ago

Simplicity Group Unveils WeDYOR: Transforming Due Diligence for Crypto Investments

Automotive Telematics Market to Exceed USD 34.52 billion by 2031 | According to Transparency Market Research Analysis

GlobeNewswire

a year ago

Automotive Telematics Market to Exceed USD 34.52 billion by 2031 | According to Transparency Market Research Analysis

Business Wire

a year ago

Form 8.3 - DX (Group) plc

Global Disposable Gloves Market Size is Estimated to Reach USD 20.1 billion by 2031, Growing at a CAGR of 8.21%: Straits Research

GlobeNewswire

a year ago

Global Disposable Gloves Market Size is Estimated to Reach USD 20.1 billion by 2031, Growing at a CAGR of 8.21%: Straits Research

Africa Smart Manufacturing Market Sees Upsurge: Comprehensive Analysis and Growth Forecasts Up to 2030

GlobeNewswire

a year ago

Africa Smart Manufacturing Market Sees Upsurge: Comprehensive Analysis and Growth Forecasts Up to 2030

SoFi Stock Soars After Company Posts First-Ever Quarterly Profit

Barrons.com

a year ago

SoFi Stock Soars After Company Posts First-Ever Quarterly Profit

The Zacks Analyst Blog Highlights Amphastar Pharmaceuticals, Abercrombie & Fitch, Cameco, CyberArk Software and LendingTree

Zacks

a year ago

The Zacks Analyst Blog Highlights Amphastar Pharmaceuticals, Abercrombie & Fitch, Cameco, CyberArk Software and LendingTree

Will Aercap (AER) Skyrocket in 2024?

Insider Monkey

a year ago

Will Aercap (AER) Skyrocket in 2024?

Baillie Gifford Bolsters Stake in ODDITY Tech Ltd

GuruFocus.com

a year ago

Baillie Gifford Bolsters Stake in ODDITY Tech Ltd

Spire Declares Dividend

PR Newswire

a year ago

Spire Declares Dividend

3 Small-Cap Healthcare Stocks to Buy and Hold Forever: January 2024

InvestorPlace

a year ago

3 Small-Cap Healthcare Stocks to Buy and Hold Forever: January 2024

PGT Innovations Named on Forbes’ America's Most Successful Small-Cap Companies List

Business Wire

a year ago

PGT Innovations Named on Forbes’ America's Most Successful Small-Cap Companies List

Travel companies are using AI to better customize trip itineraries

Fortune

a year ago

Travel companies are using AI to better customize trip itineraries

Upskilling the future of India’s construction industry

GlobeNewswire

a year ago

Upskilling the future of India’s construction industry

Intuitive Surgical Full Year 2023 Earnings: EPS Beats Expectations

Simply Wall St.

a year ago

Intuitive Surgical Full Year 2023 Earnings: EPS Beats Expectations

Zacks Investment Ideas feature highlights: Intuitive Surgical

Zacks

a year ago

Zacks Investment Ideas feature highlights: Intuitive Surgical

MPLX LP Announces Quarterly Distribution

PR Newswire

a year ago

MPLX LP Announces Quarterly Distribution

United Community Banks (UCBI) Reports Q4 Earnings: What Key Metrics Have to Say

Zacks

a year ago

United Community Banks (UCBI) Reports Q4 Earnings: What Key Metrics Have to Say

Business Wire

a year ago

Fortive Declares Regular Quarterly Dividend on its Common Stock

Business Wire

a year ago

Fortive Announces Replenishment of Share Repurchase Authorization

ACCESSWIRE

a year ago

CNH Brand Unveils Innovative Suite of Solutions for Digital Agriculture

Business Wire

a year ago

Douglas Emmett Announces 2023 Tax Treatment of Dividends

Douglas Emmett (DEI) Moves 5.3% Higher: Will This Strength Last?

Zacks

a year ago

Douglas Emmett (DEI) Moves 5.3% Higher: Will This Strength Last?

AerCap discloses cybersecurity incident

Reuters

a year ago

AerCap discloses cybersecurity incident

Texas Capital (TCBI) Q4 Earnings Miss Estimates, NII Falls Y/Y

Zacks

a year ago

Texas Capital (TCBI) Q4 Earnings Miss Estimates, NII Falls Y/Y

Texas Capital Bancshares, Inc. (NASDAQ:TCBI) Q4 2023 Earnings Call Transcript

Insider Monkey

a year ago

Texas Capital Bancshares, Inc. (NASDAQ:TCBI) Q4 2023 Earnings Call Transcript

Synovus Financial Full Year 2023 Earnings: EPS Beats Expectations

Simply Wall St.

a year ago

Synovus Financial Full Year 2023 Earnings: EPS Beats Expectations

NMI Holdings, Inc. to Announce Fourth Quarter 2023 Financial Results on February 14, 2024

GlobeNewswire

a year ago

NMI Holdings, Inc. to Announce Fourth Quarter 2023 Financial Results on February 14, 2024

Will AMN Healthcare (AMN) Beat Estimates Again in Its Next Earnings Report?

Zacks

a year ago

Will AMN Healthcare (AMN) Beat Estimates Again in Its Next Earnings Report?

Ecopetrol announces changes in senior management

PR Newswire

a year ago

Ecopetrol announces changes in senior management

Here's Why You Should Retain Affirm (AFRM) Stock for Now

Zacks

a year ago

Here's Why You Should Retain Affirm (AFRM) Stock for Now

DIRECTV and TEGNA Reach New Multi-Year Distribution Agreement

PR Newswire

a year ago

DIRECTV and TEGNA Reach New Multi-Year Distribution Agreement

WD-40's (NASDAQ:WDFC) Shareholders Will Receive A Bigger Dividend Than Last Year

Simply Wall St.

a year ago

WD-40's (NASDAQ:WDFC) Shareholders Will Receive A Bigger Dividend Than Last Year

Should You Think About Buying Progyny, Inc. (NASDAQ:PGNY) Now?

Simply Wall St.

a year ago

Should You Think About Buying Progyny, Inc. (NASDAQ:PGNY) Now?

Winners And Losers Of Q3: JFrog (NASDAQ:FROG) Vs The Rest Of The Software Development Stocks

StockStory

a year ago

Winners And Losers Of Q3: JFrog (NASDAQ:FROG) Vs The Rest Of The Software Development Stocks

Amazon Stock (AMZN) Quotes, Company News And Chart Analysis

Investor's Business Daily

a year ago

Amazon Stock (AMZN) Quotes, Company News And Chart Analysis

Here’s How the Interest Rate Movement Impacted Cable One (CABO)

Insider Monkey

a year ago

Here’s How the Interest Rate Movement Impacted Cable One (CABO)

Here's Why Investors Should Bet on Sun Life (SLF) Stock Now

Zacks

a year ago

Here's Why Investors Should Bet on Sun Life (SLF) Stock Now

Fire & Safety Products Unit Aids IDEX (IEX) Amid Cost Woes

Zacks

a year ago

Fire & Safety Products Unit Aids IDEX (IEX) Amid Cost Woes

Artemis Announces Sale of STC to IDEX

PR Newswire

a year ago

Artemis Announces Sale of STC to IDEX

Hollywood studios are expecting a year of changes: Analyst

Yahoo Finance Video

a year ago

Hollywood studios are expecting a year of changes: Analyst

ReNew Signs Contract to Sell 300 MW Solar Project at a Valuation of $199 Million

Business Wire

a year ago

ReNew Signs Contract to Sell 300 MW Solar Project at a Valuation of $199 Million

Sun Life named a #GirlsClub Top 25 Company Where Women want to Work for second consecutive year

PR Newswire

a year ago

Sun Life named a #GirlsClub Top 25 Company Where Women want to Work for second consecutive year

Fortive (FTV) Acquires EA GmbH to Boost Tektronix Business

Zacks

a year ago

Fortive (FTV) Acquires EA GmbH to Boost Tektronix Business

UniFirst Corporation (NYSE:UNF) Q1 2024 Earnings Call Transcript

Insider Monkey

a year ago

UniFirst Corporation (NYSE:UNF) Q1 2024 Earnings Call Transcript

Business Wire

a year ago

Fortive Announces Completion of EA Elektro-Automatik Acquisition

Nova to Present at the 26th Annual Needham Growth Conference

PR Newswire

a year ago

Nova to Present at the 26th Annual Needham Growth Conference

Is Fortive Corporation (NYSE:FTV) Trading At A 45% Discount?

Simply Wall St.

a year ago

Is Fortive Corporation (NYSE:FTV) Trading At A 45% Discount?

ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million

Business Wire

a year ago

ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million

Esco Technologies (ESE) is an Incredible Growth Stock: 3 Reasons Why

Zacks

a year ago

Esco Technologies (ESE) is an Incredible Growth Stock: 3 Reasons Why

AI: 2024 will mark significant enterprise adoption, pricing

Yahoo Finance Video

a year ago

AI: 2024 will mark significant enterprise adoption, pricing

Share on Social Networks: